Investigation of IVS14+1G>A polymorphism of DPYD gene in a group of bosnian patients treated with 5-fluorouracil and capecitabine

Bosnian Journal of Basic Medical Sciences

Volumn 10, Issue 2, 2010, Pages 133-139

  Cerić, Tlmur ^a   Obralić, Nermina ^a   Kapur Pojskić, Lejla ^b   Macć, Draženka ^b   Bešeija, Semir ^a   Pašić, Antes ^a   Cerić, ŠejI A ^a  

^a UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^b INGEB   (Bosnia and Herzegovina)

Author keywords

Dihydropyrimidine dehydrogenase; DPYD2A mutation; Pharmacogenetics

Indexed keywords

EID: 77953791931     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2010.2712     Document Type: Article

References (12)

1. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998;15:1200-1205.
2. Mating J. G., van Kuilenburg A. B., Haasjes H., Piersma H, Groen J. M., Uges D. R., De Vries E. G. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer 2002;86:1028-1033.
3. van Kuilenburg A. B., Haasjes J., Richel D. J., et al: Clinical impications of dihydropyrimidine dehydrogenase deficiency in patients with severe 5 FU associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 2000;6(12):4705-4712.
4. Johnson M. R., Diasio R. B. Importance of dihydropyrimidme dehydrogenase deficiency in patients exhibiting toxicity following treatment with 5-flourouracil. Adv. Enz. Regul. 2001: 41; 151-157
5. Van Kuilenburg A. B. P., De Abreu R. A., van Gonnip A.. H. Pharmacogenetic and clinical aspects of dihyd.ropyrimid.ine dehydrogenase deficiency. Ann. Clin. Biochem. 2003;40(1):41-45
6. Mc Leod H. L, Collie Duguid E. S., Vreken P., et al. Nomenclature for human DPYD alleles. Pharmacogenetics, 1998;8:455-459.
7. Van Kuilenburg A. B. P., Vreken P., Abeling N. G., Bakker H. D., Meinsma R., Van Lenthe H., et. al. Genotype and phenotype in patients with dihydropyrimidme dehydrogenase deficiency. Hum. Genet. 1999; 104:1-9.
8. Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999;104:1-9.
9. Meta-Analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.. j. Clin. Oncol. 1998;16(11):3537-3541.
10. Haga S. B., Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA, 2004;291(23):2869-2871
11. Goldstein D. B., Tate S. K, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet. 2003;4:937-947.
12. Sulzyc-Bielicka V., Bin̈czak-Kuleta A., Pioch W., Kadny J., Gziut K., Bielicki D., Ciechanowicz A. s-Fluorouracil foxicify-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol. Rep. 2008;60:238-242